CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer

The standard treatment for small cell lung cancer (SCLC) has not changed in decades. Recently, important advances have been made in immunotherapy. However, analysis of these trials suggests that only a small proportion of patients benefit from immune checkpoint blockade (ICB). Identifying these pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yichun, Hu, Yueyang, Niu, Yuchun, Sun, Lei, Guo, Linlang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891515/
https://www.ncbi.nlm.nih.gov/pubmed/35252266
http://dx.doi.org/10.3389/fmed.2022.834725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891515/
https://www.ncbi.nlm.nih.gov/pubmed/35252266
http://dx.doi.org/10.3389/fmed.2022.834725

Ejemplares similares